Bevacizumab in advanced cervical cancer

被引：0
作者：
P. J. Vlachostergios
C. N. Papandreou
机构：
[1] Lutheran Medical Center,Department of Internal Medicine
[2] University Hospital of Larissa,Department of Medical Oncology, University of Thessaly
来源：
Clinical and Translational Oncology | 2014年 / 16卷
关键词：
Vascular Endothelial Growth Factor; Overall Survival; Cervical Cancer; Bevacizumab; Clinical Target Volume;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：935 / 935
相关论文
共 27 条
[1]  
Gadducci A(2013)Tissue biomarkers as prognostic variables of cervical cancer Crit Rev Oncol Hematol 86 104-129
[2]  
Guerrieri ME(2014)Improved survival with bevacizumab in advanced cervical cancer N Engl J Med 370 734-743
[3]  
Greco C(2012)ACR Appropriateness Criteria Gynecol Oncol 125 256-262
[4]  
Tewari KS(2014) role of adjuvant therapy in the management of early stage cervical cancer Int J Radiat Oncol Biol Phys 88 101-105
[5]  
Sill MW(2013)RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma Gynecol Oncol 130 64-68
[6]  
Long HJ(undefined)Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer undefined undefined undefined-undefined
[7]  
Penson RT(undefined)undefined undefined undefined undefined-undefined
[8]  
Huang H(undefined)undefined undefined undefined undefined-undefined
[9]  
Ramondetta LM(undefined)undefined undefined undefined undefined-undefined
[10]  
Wolfson AH(undefined)undefined undefined undefined undefined-undefined
123